Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending bolus study of intravenous ABP-700 in healthy volunteers
NL-OMON40883Phase 1Active, not recruiting
- Sponsor
- Annovation Biopharma, Inc.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, double-blind trial of moxetomidate in Not applicable (2 arms), sponsored by Annovation Biopharma, Inc. Primary endpoints: Safety and tolerability, Maximum tolerated dose and 3 more. Started Apr 2014; status: active, not recruiting.
02
Drugs
moxetomidate
03
Conditions
Not applicable
Beyond the preview
Go deeper on NL-OMON40883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40883.